A personal research and treatment-planning knowledge base for long COVID (Post-Acute Sequelae of SARS-CoV-2 / PASC), built from 2025–2026 clinical literature, RCT results, and specialist protocols.
A structured, source-linked synthesis of the current state of long COVID science — organized around:
- A unified root-cause model (the "Damaged Triad" hypothesis: gut, endothelium, vagus nerve as a self-reinforcing loop)
- Treatment options by evidence tier (RCTs, case series, experimental)
- Practical protocols for specific drugs (e.g., bupropion) and lifestyle interventions
- Curated primary sources organized by topic
Built collaboratively with Claude (Anthropic) using research and reasoning across the 2025–2026 literature.
- ❌ Medical advice
- ❌ A substitute for a physician
- ❌ A peer-reviewed publication
- ❌ Guaranteed accurate — this is a working understanding subject to update as new evidence emerges
All content is for educational/personal-planning purposes only. Consult a qualified physician before making any medical decisions.
long_covid/
├── README.md ← You are here
├── CLAUDE.md ← Instructions for AI collaboration
├── LICENSE ← MIT
├── .gitignore ← Personal notes excluded by default
├── docs/ ← Public research content
│ ├── 01-triad-model.md ← Root-cause hypothesis (hardware layer)
│ ├── 02-treatments.md ← Treatment evidence tiers
│ ├── 03-bupropion-guide.md ← Bupropion practical guide
│ ├── 04-unified-model.md ← The Stuck Sickness Program (full unified RCA)
│ ├── 05-mast-cell-gut-protocol.md ← Food-reactive / mast-cell phenotype: anatomy, drugs (India), tests
│ └── sources.md ← Curated references
└── personal/ ← Personal application (gitignored)
├── README.md ← Personal entry point
├── profile.md ← Personal symptom profile
└── action-plan.md ← Personal 90-day plan
New readers should go:
- docs/04-unified-model.md — The full unified RCA (start here)
- docs/01-triad-model.md — The hardware layer (which tissues and why)
- docs/02-treatments.md — What actually works and doesn't
- docs/03-bupropion-guide.md — Deep-dive on one high-relevance drug
- docs/05-mast-cell-gut-protocol.md — The gut mast-cell / vagal-afferent phenotype and its protocol
- docs/sources.md — Primary literature
Long COVID is a self-sustaining inflammatory loop between the gut epithelium, vascular endothelium, and vagus nerve — three ACE2-receptor-rich tissues SARS-CoV-2 preferentially damages. Once damaged, each leg feeds injury to the other two, forming a positive-feedback cycle that continues long after the acute virus is cleared. Every observed long COVID phenomenon — microclots, neuroinflammation, mitochondrial dysfunction, serotonin depletion, dopamine loss, HPA flattening, POTS, autoantibodies, EBV reactivation, PEM — is downstream of this loop. Full recovery requires breaking the loop at multiple points simultaneously, which explains why single-drug trials keep failing while multi-modal protocols at LC clinics succeed.
See docs/01-triad-model.md for the full model, mapped observations, and mechanistic evidence.
| Finding | Source |
|---|---|
| Fluvoxamine reduces LC fatigue significantly (RCT) | REVIVE trial, Annals Int Med March 2026 |
| Dopamine terminal density loss in striatum documented | 2026 Nature-published imaging study |
| Fibrinaloid microclots — 4 distinct subtypes identified | Pretorius group, PolyBio Symposium 2026 |
| Nicotinamide Riboside modest fatigue benefit (RCT) | Lancet eClinicalMedicine 2025 |
| COVIVA, Neurol Ther 2026 (n=45) + Percin 2025, Vienna 2025, Mayo nVNS | |
| Gut viral RNA/antigen persistence documented to ~22–30 months; nothing at 4–5 years; blood antigen does not track symptoms | Peluso 2024 Sci Transl Med; Hany 2024; Mateu 2026 |
| Metformin does NOT treat existing LC | REVIVE trial 2026 |
| Extended Paxlovid does NOT treat LC | RECOVER-VITAL 2025 |
| Antihistamine (H1+H2): small (−1.5 FAS points), transient fatigue benefit in unselected LC; food-reactive subgroup untested | STIMULATE-ICP, Wall 2026, Lancet Infect Dis (n=778, open-label) |
| Bifidobacterium synbiotic (SIM01) ~doubles odds of improvement in fatigue, memory, concentration, GI symptoms | Lau 2024, Lancet Infect Dis (RCT, n=463) |
| Gut mast-cell activation + persistent viral protein in ileal biopsies 15–22 months post-infection | Augustin 2026, Mucosal Immunol |
| Stellate ganglion block — 56% improved in largest series (n=102), durable in ~1/3 of responders, 25% transient AEs; sham RCTs started 2026 | Chiang 2025 Cureus; Peddireddy 2026 SR; NCT07468604 |
This is a personal research project. If you're another long COVID researcher, patient, or clinician who wants to suggest additions/corrections:
- Open an issue with the specific citation
- Reference primary literature (RCTs, meta-analyses, mechanism papers) rather than blog posts where possible
- Flag anything that turned out to be wrong so I can update
MIT — free to use, modify, redistribute with attribution. See LICENSE.
- NIH RECOVER Initiative for the trial infrastructure
- Patient-Led Research Collaborative for pushing the field forward
- Berlin Cures, Yale (Arnsten group), Pretorius group, RTHM clinic for mechanism + treatment research
- Anthropic / Claude for research assistance in compiling this synthesis
This is a living document. Last updated: 2026-08-18.